Rt Hon. Lord David Willetts
Executive Chair of The Resolution Foundation and Former Minister for Universities and Science
Rt Hon. Lord David Willetts
Executive Chair of The Resolution Foundation and Former Minister for Universities and Science
The Rt Hon. Lord David Willetts is the Executive Chair of the Resolution Foundation. He served as the Member of Parliament for Havant (1992-2015), as Minister for Universities and Science (2010-2014) and previously worked at HM Treasury and the No. 10 Policy Unit.
Lord Willetts is a visiting Professor at King’s College London, Governor of the Ditchley Foundation, Chair of the British Science Association and a member of the Council of the Institute for Fiscal Studies. He is an Honorary Fellow of Nuffield College Oxford.
Lord Willetts has written widely on economic and social policy. His book ‘The Pinch’ was published in 2010. He has just completed a book on universities which will be published by Oxford University Press in November.
Co-founder and Deputy Chairman of Abcam plc
Jonathan, co-Founder and currently Deputy Chairman of Abcam plc, is an entrepreneur and investor and is passionate about supporting UK life science and high-tech start-ups. He has provided considerable investment and support to over 40 companies and has assisted three technology companies to IPO on the London AIM Stock exchange.
Jonathan gained his doctorate in Molecular Genetics at Leicester University after graduating in Applied Biology at Bath. From 1992–95, he was a post-doctoral researcher at Bath, following which he worked at the University of Cambridge in the lab of Professor Tony Kouzarides researching the molecular basis of breast cancer. He identified the market opportunity for supplying high-quality antibodies to support protein interaction studies, and in 1998, founded Abcam with David Cleevely and Professor Tony Kouzarides.
Jonathan is also a non-executive director of Horizon Discovery, Repositive, HealX and Syndicate Room. He is also Chairman of Axol Bioscience, Cambridge Allergy Therapy, PhoreMost and DefiniGEN, and sits on the advisory board of Desktop Genetics.
In 2015 Jonathan, with Professor Tony Kouzarides, co-founded the Milner Therapeutics Institute at the University of Cambridge. Also in 2015 he co-founded, with Professor Laurence Hurst, the Milner Institute for Evolution at the University of Bath.
Dr Richard Mason
Head of Johnson & Johnson Innovation, London
Richard is the Head of Johnson & Johnson Innovation Centre, London. He is responsible for Johnson & Johnson Innovation across EMEA and is Head of the London Innovation Center.
Prior to joining Johnson & Johnson Innovation, he was CEO of XO1 Limited until the company was acquired by Janssen in March 2015. Prior to his role at XO1, Richard was Head of Strategy and Business Development at specialist pharmaceutical and medical device company BTG Plc, where he led its transformation into a leading interventional medicine company through multiple acquisitions. Richard also served as an Executive-in-Residence for Advent Venture Partners LLC where he was a turnaround CEO for several portfolio companies. Previously he was Senior Vice President, Business Development at Cambridge Antibody Technology (CAT).
Richard trained in medicine at the St Bartholomew’s Hospital Medical College and worked in clinical practice in internal medicine before entering the biotechnology industry. He also has a degree in immunology from UCL and an MBA from The Judge Business School, University of Cambridge, where he is currently a Fellow in Healthcare Management and teaches the MBA elective in biotechnology and pharmaceuticals.
Richard resides near Cambridge, UK. In his spare time Richard enjoys skiing, running, flying and sailing.
Dr James Sabry
Senior Vice President, Genentech Partnering
James Sabry is Senior Vice President, Genentech Partnering, where he oversees both Business Development and Alliance Management Groups. These groups have been considered to be some of the best in the industry.
Sabry grew up in Toronto, Canada and received an M.D. from Queen's University in Kingston, Canada. Completing an internship in internal medicine at Toronto Western Hospital, he moved to Harvard Medical School where he completed a residency in Neurology, being named Chief Resident in Neurology in 1987.
He then moved to San Fransisco and, in 1994, completed a Ph.D. in Neuroscience in the Biochemistry Department at UCSF while also holding an adjunct clinical appointment in the Department of Neurology.
James was President and CEO of Cytokinetics until 2007. During that time, he grew the company from inception to over 200 employees and took the company public on NASDAQ in 2004. In 2007, he became Chairman of the Board of Directors and a member of their Scientific Advisory Board.
In 2008, he became President and CEO of Arete Therapeutics, a company focused on the discovery and development of therapeutics for diabetes.
In 2010, Sabry moved to Genentech to take his current position. He maintains membership on the Scientific Advisory Board of Cytokinetics. He is also on the external advisory board of QB3 at UCSF.
Dr Will West
Executive Chairman of CellCentric Ltd.
Will is Executive Chairman of CellCentric Ltd, an epigenetic-based cancer drug discovery and development company, originally spun out of Cambridge University. The lead product is a small molecule inhibitor of p300/CBP for the aggressive form of prostate cancer (CRPC), as well as other tumour types including bladder and haematological cancers. Additionally, Will is President & CEO of Cancer Targeting Systems Inc., a non-viral gene product company for cancer imaging and treatment, founded out of Johns Hopkins School of Medicine, Baltimore.
Will gained a PhD in Immunology and Virology sponsored by Unilever (UniPath), before holding a post-doctoral position at the National Institute of Biological Standards and Control (NIBSC). He went on to Procter & Gamble Healthcare, where he was responsible for clinical development in a number of therapeutic areas, including respiratory and GI. Will holds a Masters degree in Clinical Research as well as an MBA from London Business School.
Will is on the Board and Executive Committee of the BioIndustry Association (BIA). Previously he was on the Council of the BBSRC, which distributes £500m a year on bioscience research on behalf of the Government. He is a co-founder of Angels 4 Life Sciences, an investor forum which works closely with Angels in MedCity. He has mentored for OneStart, including two overall competition winners.
Managing Director, MediCity
Senior Vice President, Innovation and Development, BioCity Group
Managing Director, MediCity
Senior Vice President, Innovation and Development, BioCity Group
David applies 35 years of healthcare experience with a focus on technology translation and new venture creation to harness entrepreneurship to address global health and wellbeing challenges.
His primary experience was gained as a biomedical scientist within the UK National Health Service and clinical diagnostics innovation within Amersham International and Johnson & Johnson. He has led start-ups, including an Oxford University spin-out, applying nanotechnology for medical devices and advanced sun-care products. Within Philips, David led personalised medicine and pro-active healthcare businesses.
David directly promotes healthy lifestyles through sport as a coach and Great Britain Cross Triathlon
Dr Yong Jun Liu
Global Head of Research, Sanofi
Dr. Liu has over 25 years of experience in the pharmaceutical industry and at leading medical research centers. From 1991 to 1997, he was a Senior and then Principal Scientist at Schering-Plough's Laboratory for Immunological Research.
Dr. Liu held a Principal Staff Scientist position at the DNAX Research Institute in California until 2002, when he became the founding director of the Cancer Immunology Research Institute at the University of Texas MD Anderson Cancer Center. At MD Anderson, he also served as the Chair of the Department of Immunology, building the leading immunology program in the U.S.
In 2011, Dr. Liu joined the Baylor Research Institute as Vice President and Chief Scientific Officer, and Director of the Baylor Institute for Immunology Research. He was appointed Head of Research at MedImmune in January, 2014. He has been the Global Head of Research at Sanofi since April, 2016.
Andreas Hougaard Laustsen
Head of the Tropical Pharmacology Lab, Technical University of Denmark
Andreas Hougaard Laustsen is a Postdoctoral Fellow & Head of the Tropical Pharmacology Lab, which he has started at the Technical University of Denmark. He specializes in antibody discovery, toxinology, and snakebite antivenom, and holds an M.Sc.Eng in Pharmaceutical Engineering from the Technical University of Denmark and a PhD in Molecular and Cellular Pharmacology from the University of Copenhagen.
He is a co-founder of 5 biotech companies: Biosyntia, VenomAb, Antag Therapeutics, Chromologics, and Bactolife. Combined, his ventures and research activities have attracted over GBP 5 million in funding. Andreas is recognized as Denmark's Coolest Engineer, a Top 10 biotech entrepreneur under 30 in Europe, a Top 6 entrepreneurial academic in Europe under 35, and features on Forbes 30 under 30 list for 2017.
Partner and Co-founder, Medicxi
Prior to co-founding medicxi, Kevin was a partner with Index Ventures for 12 years, having joined the firm’s life sciences team in 2003. Kevin spearheaded Index’s very first experimental asset-centric investment, in PanGenetics, which was later acquired by Abbott Pharmaceuticals. He is currently chairman of Levicept Ltd., Apcintex and Crescendo Biologics as well as being a board member of several other startups.
Prior to joining Index, Kevin was with Cambridge Antibody Technology (CAT), where he was appointed Head of Research in 1994 and, in 1997, Research Director and Chief Technology Officer. He led the development of CAT's platform technologies and their application in the discovery of a number of human antibodies, two of which are now on the market: Humira (Abbott Pharmaceuticals) and Benlysta (GlaxoSmithKline). Kevin was part of the management team that floated CAT on the London Stock Exchange; it was subsequently acquired by AstraZeneca.
Kevin received a BSc in Molecular Biology from Edinburgh University and a PhD from Cambridge University.
Professor Chris Lowe
Director, Cambridge Academy of Therapeutic Sciences (CATS)
Professor Christopher R. Lowe was founder Director of the Institute of Biotechnology at the University of Cambridge and conducts research in both diagnostics and therapeutics in the healthcare biotechnology sector. He is a fellow of the Royal Academy of Engineering, the Institute of Physics and the Royal Society of Chemistry. He has 395 peer-reviewed publications, 8 books and monographs, >100 patents and has supervised >95 PhD students and has a number of national and international prizes: “Queen’s Award for Technological Achievement”; “Queen’s Anniversary Prize for Higher and Further Education”; “Most
Entrepreneurial Scientist of the UK”; OBE in the Queen’s New Year Honours; BBSRC Commercial Innovator of the Year in 2011.
He has been the driving force for the establishment of 11 spin-out companies including ProMetic Biosciences Inc (Market Cap $1.9- 2.1B), Cambridge Sensors Ltd, Paramata Ltd, Psynova Neurotech Ltd and Royale Therapeutics Ltd., has a number of directorships and fosters entrepreneurship within the University via a Master’s in Bioscience Enterprise, the University’s Seed Fund Committee and other Business School and student-led activities. He is active in various government committees and in a number of legal and entrepreneurial roles. His group's primary research interest is in healthcare biotechnology, particularly where it is applied to the biopharmaceutical, sensors and diagnostics and enzyme and microbial technology sectors. The work is highly multidisciplinary and not only covers aspects of molecular biology, biochemistry, microbiology, chemistry, physics, electronics and engineering, but also the entire range from fundamental science to strategic and applied science. He is currently Director of the newly established Cambridge Academy of Therapeutic Sciences (CATS) within the University of Cambridge.
Dr Ian Tomlinson
Chairman, Apollo Therapeutics and Chairman, Stevenage Bioscience Catalyst
Ian Tomlinson has over 25 years of experience in the life sciences sector from academic research to biotech startup to big pharma. He founded Domantis Limited with Sir Gregory Winter, which was acquired by GSK for $454 million. He then served as Senior VP, Head of Worldwide Business Development and Head of Biopharm R&D at GSK.
Following he departure from GSK earlier this year, he is now Chairman of the Board at the Stevenage Bioscience Catalyst, UK’s first open innovation biomedical campus. He is also Chairman of the Investment Committee for Apollo Therapeutics, a £40 million fund dedicated to turning academic biotechnologies into novel medicines in collaboration with Astrazeneca, GSK, J&J, Imperial College, UCL and the University of Cambridge.
Dr Tomlinson graduated from Trinity College, Cambridge, UK. He then spent 11 years at the MRC Laboratory of Molecular Biology, where he worked on antibody genes, antibody structure and various antibody technologies prior to starting his career in industry.
Dr Kai Stoeber
Vice President, Global Innovation, Shionogi Europe
Dr Kai Stoeber is Vice President of Global Innovation at Shionogi Europe and is an expert in cancer biology and biomarkers. Dr Stoeber received his M.Sc. in Biological Sciences from the University of Bonn and his Ph.D. from the University of Cambridge. His Ph.D. studies in the laboratory of Ron Laskey showed that dysregulation of the DNA replication initiation machinery is a major early event in the genesis of cancer, and led to a succession of translational spin-offs rooted in the basic biology of cell division. Insights into the mechanisms controlling DNA replication formed the basis for a range of promising diagnostic technologies developed in collaboration with biotech companies. From 2002-2014, Stoeber was co-principal investigator of the Chromosomal Replication Group at University College London. His work there with Gareth Williams led to a drug discovery programme focused on one of the kinases that jumpstart DNA replication initiation in partnership with CRUK’s own drug discovery lab, and resulted in the licensing of promising lead compounds to a major biopharma company for further development. A further spin-off from his research has been a novel cell cycle biomarker algorithm that identifies cell cycle kinetics in dynamic tumor cell populations and predicts response to cell-cycle phase-directed chemotherapeutic agents and selected targeted therapies. Dr Stoeber joined the Japanese pharmaceutical company Shionogi in 2014 where he identifies and evaluates transformative technologies as well as new targets or molecules from external sources in academia and biopharma. He remains an advocate of the importance of translational medicine in increasing the accuracy of early stage clinical development and reducing the risk of failure at later stages.
Prof Alan Barrell
Founding Partner, Cambridge Worldwide Associates
PROFESSOR ALAN BARRELL DBA., FRSA., Queen’s Award
After three score years and more than ten, Alan Barrell finds it hard to say “no” to innovation and entrepreneurial ideas which arrive in his life by all known communication means daily.
Biologist with experience in NHS medical technology, turned salesman turned businessman, entrepreneur, venture capitalist fund manager, and labelled now “pracademic”, Alan is a champion of the next generation and the vision of A World Without Borders – through Education Without Borders and Open Innovation. Entrepreneur in Residence at the Centre for Entrepreneurial Learning Judge Business School University of Cambridge, Visiting Professor at University of Sunderland, Portsmouth in UK and International Executive Fellow University of Essex , and in China Guest Professor at Xiamen University, Shanghai University, Shanghai College of Science and Technology and University of International Business and Economics Beijing and School of Economics Liaoning University Shenyang. International Research Fellow at Laurea University Helsinki and Lahti University in Finland, and at the Tohoku Fukushi University Sendai Japan, Alan is also engaged in support of NHS Healthcare Reforms after being Chair of NHS Health Enterprise East Ltd for eight years. His next generation work extends to Board Membership / shareholdings in four early stage health care companies and to having been Chairman of Trustees of NACUE – National Association of College and University Entrepreneurs and advisor to Start Up Generation International and Youth Business China. In his spare time raises money for the charitable causes he supports. Bestselling book out July 2013 – co-authored with David Gill and Martin Rigby – “Show Me The Money – how to raise the money needed to get your business off the ground”, since revised to cover the latest in Alternative Finance. Knighted in Finland by the President there in 2012 for services to education – Knight First Class of the Order of the White Rose of Finland having earlier been one of the first ten recipients of The Queen’s Award for Enterprise Promotion. Very proud to be an Advisory Board Member to Innovation Forum and MedCity London. His articles in Cambridgeshire Business and national publications “Sharing China’s Dream” displays his deep interest in China and its history and his love of the country and its people.
Travels widely but always loves coming home to Cambridge and visiting Yorkshire.
Independent Consultant and Entrepreneur in Residence at UMIP, Manchester
Martino is now an Independent Consultant, based in Manchester. He currently has a part-time role as Entrepreneur in Residence at UMIP, Manchester. From June 2011- July 2017, Martino was the first CEO of the Stevenage Bioscience Catalyst an ambitious concept to develop an Incubator and Accelerator, followed by a world class Science Park for the Life Sciences sector. Martino has a PhD in Biochemistry from Cardiff University and spent 4 years at Baylor College of Medicine, Houston, TX in Cardiovascular research. Martino joined Amersham International in 1991 and subsequently went on to manage the R&D Technology Transfer Group, based in Cardiff and developing high throughput screening technologies for the Pharmaceutical sector. Following the merger of Amersham with Pharmacia Biotech, Martino became the Science Director for the Cardiff site, Martino then became a Business Manager for Manchester Biotech Ltd. and subsequently Manchester Innovation Ltd. in June 1999. When the Universities of Manchester and UMIST merged, he became Managing Director of UMIC and MICL and is also currently a Board member of UKBI. Martino was also acting Chairman for a start-up company, sri Forensics Ltd (2011-2014) and has previously been on the Board of Cartesian Technologies , BIONOW Steering Committee and was also a non -executive Director for Queen Mary Bioenterprise Ltd (2009-Aug 2010).. Martino has also been a Board member of the Hertfordshire LEP. Most recently, Martino has been on the Trust Board for the North Herts Studio Schools (Stevenage, Letchworth and Thomas Alleyne Schools) and on the Local Governing Body for the Da Vinci Studio School Stevenage. Martino has also been appointed to the Life Science Wales Hub Board as a Non –Executive). Martino is involved in funding application and appraisals for Innovate UK, Astia and NC3Rs.
Global Innovation Assistant, Shionogi Europe
Yoshi is an advocate of Open Innovation. His work at Shionogi Europe involves identifying innovation and open science opportunities in UK and the continental Europe, and developing and managing research collaborations with academia, biotech and pharma partners. Yoshi obtained a PhD in Behavioural Neuroscience from the University of Cambridge, and subsequently worked as a research scientist at the university. Aside from working in his research laboratory, he served as a committee chair of a university-wide inter-disciplinary science seminar series. He was also involved in activities of the Innovation Forum, building professional networks of academic and industry experts and facilitating inter-sector conference organisations in Cambridge. Through these activities, Yoshi discovered his interest in working at a translational junction between research and application. This eventually led him to his current role in the Global Innovation Office, where he exercises his scientific knowledge to promote the transfer of discoveries from laboratories to clinical practice.
Shionogi & Co., Ltd., is a major research-driven international pharmaceutical company with two core target therapeutic areas: infectious diseases and Pain/CNS disorders, and several frontier focus areas including obesity/geriatric metabolic diseases and oncology/immunology. For more information, please visit www.shionogi.co.jp/en/ and www.shionogi.eu.
Professor Jackie Hunter
CEO, Benevolent Bio
Jackie Hunter is the Chief Executive Officer of Benevolent Bio. Benevolent
Bio unites traditional pharmaceutical development methodology with
Artificial Intelligence to augment the research capabilities of its drug
scientists so that they can gain new insights to increase the efficiency of
Jackie has over thirty years of experience in the
bioscience research sector, working across academia and industry
including leading neurology and gastrointestinal drug discovery and early
clinical development for GlaxoSmithKline. She founded OI Pharma
Partners in 2010 to support the life science sector in harnessing the
power of open innovation and most recently was Chief Executive of the
Biotechnology and Biological Sciences Research Council. She holds a
personal chair from St George's Hospital Medical School, which was
awarded in recognition of her contribution to bioscience research. In
2010 she was awarded a CBE in the Queen's Birthday Honours list for
Services to the Pharmaceutical Industry.
Dr Dave Tapolczay
Chief Executive, LifeArc
Dr Dave Tapolczay was appointed Chief Executive at LifeArc (previously MRC Technology) in 2007. Prior to that he was CEO at Medeor Pharma Ltd. and held various C-level positions, including at GSK, Millennium Pharmaceuticals, SAFC Pharma and Zeneca. He holds a post-doctorate degree in chemistry from the University of Oxford.